AilseVax
@ailsevax.com
Ailsevaxis based on the 3 core elements: neo-antigens discovery, cancer vaccine development, effective adjuvants and delivery platforms. AilseVax are developing innovations across all three domains to develop the next generation of cancer vaccine therapies.Founded by oncologists, immunologists, data scientists and an experienced management team with excellent track-record in building multiple successful life sciences ventures.
AilseVax's Company Logos
AilseVax's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#315378
San Juan
49, 83, 120
211, 42, 33
59, 31, 0, 53
#83BDE3
Cornflower
131, 189, 227
204, 63, 70
42, 17, 0, 11
#050E1F
Black Pearl
5, 14, 31
219, 72, 7
84, 55, 0, 88
About AilseVax
AilseVax is a pioneering brand at the forefront of cancer vaccine development. Founded by experienced oncologists, immunologists, and data scientists, AilseVax is dedicated to innovation across three core elements: neo-antigens discovery, cancer vaccine development, and effective adjuvants and delivery platforms. Their team of world-recognized scientists and advisors are experts in cancer biology, neo-antigen discovery, vaccine adjuvants, and early phase clinical trials. AilseVax's unique and cutting-edge science is based on the development of advanced antigen formulations to enhance antigen presentation and promote anti-tumour immune responses.
AilseVax has developed proprietary technologies such as AVX101 and AltRNA8Vā¢ to promote protective cell-mediated immunity and identify cancer-specific antigens. Their pipeline focuses on developing cancer vaccines that work in multiple patient populations, with promising clinical indications for various types of cancer. Recently, AilseVax secured Ā£1.5M seed funding to advance cancer vaccine development and continues to build partnerships with leading academic institutes and companies to expand their scientific innovation and development strategies.
Company type
Partnership
Year founded
2021
Company size
2-10 employees
